Abstract:Primary sclerosing cholangitis (PSC) is a rare chronic cholestatic liver disease of unclear cause. Until now, there are no effective therapies for patients with PSC. A number of studies have evaluated the effects of immune-modulating therapies on the treatment of PSC. However, clinical benefits of these treatments in PSC patients are controversial and inconclusive. We performed a systematic review and meta-analysis to assess the efficacy and adverse effects of immunomodulators in adult patients with PSC based on prognostic markers (alkaline phosphatase (ALP) and total bilirubin), liver function marker (aspartate aminotransferase (AST)) and adverse event (AE) rates. Twenty-one studies (seven randomized controlled trials (RCT) and fourteen observational studies) involving 737 patients were included in this analysis. Immune-modulating therapies significantly reduced ALP level in PSC patients, but not to normal level. AST level was non-significantly decreased, while no effect was observed on total bilirubin level after treatments in PSC patients. In 16 studies reporting AEs, an average of 16.1% patients had severe AEs, resulting in discontinuation of therapies. Importantly, subgroup analysis further indicated that immune-modulating therapy significantly reduced ALP or AST levels in PSC patients with high baseline levels of ALP (over 420 U/L, ˃ three times the upper limit of normal (ULN)) or AST (over 80 U/L, ˃ two times the ULN), but had no effect in patients with low baseline levels. Compared to other immune-modulating therapies, immunosuppressants had the most significant effect on reducing ALP and AST levels in PSC patients but was associated with the highest incidence of severe AEs of 24.9%. Glucocorticoids showed a positive effect by significantly reducing ALP levels with the minimal AE rate of 6.1%. In conclusion, immune-modulating therapies could improve the prognostic marker of cholestasis (ALP level) in patients with PSC, especially in those of worse liver function. These findings suggest patients with high baseline level of ALP (˃ 420 U/L) and AST (˃ 80 U/L) respond better to immune-modulating therapy compared to those with low level of ALP and AST. Future RCTs would be needed to include different dosing regimens, a longer treatment duration and follow-up period, and patients stratified by liver function to obtain solid conclusion.

S1913 Efficacy and Safety of Seladelpar in Primary Biliary Cholangitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Seladelpar in primary biliary cholangitis

S1881 Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Interim Results for 2 Years From the ASSURE Study

Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis

Clinical Analysis of Primary Biliary Cirrhosis: a Report of 31 Cases

Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis

Clinical Efficacy of Ursodesoxycholic Acid for the Treatment of Primary Biliary Cirrhosis: a Meta-analysis

A Multicenter, Randomized, Double-Blind Trial Comparing The Efficacy And Safety Of Tudca And Udca In Chinese Patients With Primary Biliary Cholangitis

Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis

New Treatment Paradigms in Primary Biliary Cholangitis

PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases

Revisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis

Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis

Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics

Advances in the Treatment of Primary Biliary Cholangitis

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape

S1996 Statins Protect Against Major Liver Events in Patients With Primary Biliary Cholangitis

Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis